STAAR Surgical Co

STAA is exhibiting a bearish medium-term structure marked by lower highs and lower lows below the falling 9EMA and 20EMA, with short-term momentum negative and no exhaustion signals. We will execute sell-side engagement on rallies into the 9/20 EMA region, leveraging rejection at moving-average resistance to preserve the downtrend.

• ↑Q1 2026 net sales up 119.6% YoY to $93.5M, led by U.S. and China demand.
• ↑Adjusted EBITDA turned positive at $24.4M in Q1 2026 versus a $26.3M loss year-ago; gross margin improved to 73.6%.
• ↓Reported $80.45M net loss in 2025, signaling sustained margin pressures.